Want to see IMTX full AI Analyst Report?
IMTX Stock Chart & Stats
$11.17
<$0.01(0.14%)
At close: 4:00 PM EST
$11.17
<$0.01(0.14%)
Day’s Range― - ―
52-Week Range$5.05 - $12.41
Previous CloseN/A
Volume408.80K
Average Volume (3M)488.70K
Market Cap
$1.34B
Enterprise Value$821.67M
Total Cash (Recent Filing)$454.04M
Total Debt (Recent Filing)$15.10M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 19, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding134,096,570
10 Day Avg. Volume418,873
30 Day Avg. Volume488,702
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.26
Price to Sales (P/S)22.65
P/FCF Ratio-6.21
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue22.03
Enterprise Value/Gross Profit22.03
Enterprise Value/Ebitda-4.06
Forecast
1Y Price Target
$19.64Price Target Upside75.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$37.39M
Bulls Say, Bears Say
Bulls Say
Proprietary Target-discovery Platform & Clinical ProgressImmatics’ XPRESIDENT-driven programs (exemplified by IMA401 published in Nature Medicine) reflect platform-enabled target selection and clinical proof-of-concept. Durable responses and tolerability at RP2D materially de-risk programs and strengthen long-term pipeline value and partner interest.
Low Financial LeverageVery low debt levels give Immatics optionality to fund R&D through partnerships, grants or capital markets without heavy interest burdens. For a clinical-stage biotech, low leverage reduces short-term solvency risk and supports sustained investment in pivotal trials over the next 2–6 months.
Broad Target Applicability (PRAME) Across CancersHigh PRAME prevalence across many tumor types creates a structurally large addressable market and allows a single TCR franchise to be extended across adult and pediatric indications. This breadth supports durable commercialization potential and justifies continued investment in registrational pathways.
Bears Say
High Cash Burn And Negative Cash FlowSustained negative operating and free cash flow at ~-$184M to -$188M TTM indicates heavy cash consumption to advance trials. Without timely milestone payments or financing, the burn rate escalates funding risk and may force dilutive capital raises within months, impacting strategic flexibility.
Volatile And Declining Collaboration RevenueReliance on collaboration and milestone payments creates lumpy revenue. A sharp one-year drop in collaboration receipts reduces near-term inflows, worsening runway pressure and increasing dependence on external financing or new deals to sustain R&D programs over the medium term.
Deep And Persistent Losses, Weak ReturnsVery large negative margins and returns reflect R&D intensity without commercial sales. Persistently deep losses erode equity and heighten dilution risk if product approvals are delayed, limiting the company’s ability to self-fund growth and making long-term profitability contingent on successful late-stage outcomes.
Immatics News
IMTX FAQ
What was Immatics N.V.’s price range in the past 12 months?
Immatics N.V. lowest stock price was $5.05 and its highest was $12.41 in the past 12 months.
What is Immatics N.V.’s market cap?
Immatics N.V.’s market cap is $1.34B.
When is Immatics N.V.’s upcoming earnings report date?
Immatics N.V.’s upcoming earnings report date is Aug 19, 2026 which is in 41 days.
How were Immatics N.V.’s earnings last quarter?
Immatics N.V. released its earnings results on May 12, 2026. The company reported -$0.491 earnings per share for the quarter, missing the consensus estimate of -$0.453 by -$0.039.
Is Immatics N.V. overvalued?
According to Wall Street analysts Immatics N.V.’s price is currently Undervalued.
Does Immatics N.V. pay dividends?
Immatics N.V. does not currently pay dividends.
What is Immatics N.V.’s EPS estimate?
Immatics N.V.’s EPS estimate is -0.48.
How many shares outstanding does Immatics N.V. have?
Immatics N.V. has 134,096,570 shares outstanding.
What happened to Immatics N.V.’s price movement after its last earnings report?
Immatics N.V. reported an EPS of -$0.491 in its last earnings report, missing expectations of -$0.453. Following the earnings report the stock price went down -1.3%.
Which hedge fund is a major shareholder of Immatics N.V.?
Currently, no hedge funds are holding shares in IMTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immatics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.64 (75.83% Upside)
$19.64 (75.83% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
85.36%
12-Months-Change
Fundamentals
Return on Equity
-45.27%
Trailing 12-Months
Asset Growth
-9.70%
Trailing 12-Months
Company Description
Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
IMTX Stock 12 Month Forecast
Average Price Target
$19.64
▲(75.83% Upside)
Technical Analysis
Ownership Overview
―
Insiders
10.89% Mutual Funds
61.55% Other Institutional Investors
26.93% Public Companies and
Individual Investors